A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China
The study showed promising efficacy and safety of dinutuximab beta as the first-line maintenance immunotherapy for pediatric patients with HR-NB. Notably, the combination of dinutuximab beta with GM-CSF and VIT chemotherapy could be used for treating patients who did not achieve CR after previous multimodal therapy.
Authors
- Xuedi Yu
- Junjie Ge (ORCID: https://orcid.org/0000-0002-1561-4852)
- Suyi Kang (ORCID: https://orcid.org/0000-0001-9256-6527)
- Jingfu Wang
Institutions
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- BMC Pediatrics
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1186/s12887-025-05568-x
- Citations
- 3
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.17